Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19.
J Alzheimers Dis
; 76(1): 27-31, 2020.
Article
in English
| MEDLINE | ID: covidwho-637281
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Health Personnel
/
Coronavirus Infections
/
Alzheimer Disease
/
Patient Safety
/
Personal Protective Equipment
/
Betacoronavirus
Type of study:
Diagnostic study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Alzheimers Dis
Journal subject:
Geriatrics
/
Neurology
Year:
2020
Document Type:
Article
Affiliation country:
JAD-200684
Similar
MEDLINE
...
LILACS
LIS